HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XTLB
XTL Biopharmaceuticals Ltd.
There isn't enough reported data to score XTLB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XTLB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Stable | |
| Strong |
XTLB's balance sheet is currently strong, and its cash flow is stable, but its profitability is under pressure. There isn't enough data to rate its revenue.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XTLB PE Valuation
XTLB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XTLB Forward outlook
There aren't enough analyst estimates for XTLB to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
XTLB has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus XTLB down 155%.
XTLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.88 | +$2.40 |
| Q3 2024 | -$3.04 | +$3.68 |
| Q2 2024 | -$2.08 | +$6.40 |
| Q1 2024 | -$1.12 | +$7.04 |
| Q4 2023 | -$5.28 | -$1.28 |
| Q3 2023 | -$6.72 | -262% |
| Q2 2023 | -$8.48 | -266% |
| Q1 2023 | -$8.16 | -343% |
XTLB is still losing money, but far less than before: $2.88 per share over the past year, against $16.16 at its worst in early 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XTLB Quarterly Revenue
XTLB's revenue is growing: $289,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -281% | N/A |
| Q3 2024 | -472% | N/A |
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
XTLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
| Q4 2023 | $0 | $0 |
| Q3 2023 | $0 | $0 |
| Q2 2023 | $0 | $0 |
| Q1 2023 | $0 | $0 |
XTLB's free cash flow has been positive every quarter for six years: $0 over the past year, against $0 the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XTLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XTLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +99.5K shares |
| 1 year | +29% | +99.5K shares |
| 3 years | +22% | +79.7K shares |
| 5 years | +37% | +119K shares |
| Available history | +37% | +119K shares |
XTLB has 440,101 diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
XTLB hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XTLB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -6.6x | Net Cash |
| Q3 2018 | -0.9x | Net Cash |
| Q2 2018 | -2.6x | Net Cash |
XTLB has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XTLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 2.2 | Oversold |
XTLB's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XTLB PE vs Healthcare Sector
| Metric | XTLB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTLB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XTLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.89 | 13% below |
| 20 week MA | $2.39 | 31% below |
| 50 week MA | $2.69 | 39% below |
| 100 week MA | $4.01 | 59% below |
| 200 week MA | $5.16 | 68% below |
XTLB is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over XTLB on returns for 2026, with the stronger performance.
XTLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.20 | $11.0 | +112% |
| 2021 | $11.0 | $10.9 | -1.1% |
| 2022 | $10.9 | $4.76 | -56% |
| 2023 | $4.76 | $4.04 | -15% |
| 2024 | $4.04 | $8.28 | +105% |
| 2025 | $8.28 | $2.96 | -64% |
| 2026 YTD | $2.96 | $1.64 | -45% |
XTLB's yearly returns have swung widely, from +112% in 2020 to −64% in 2025. It's down 45% so far in 2026.